title: Progress toward the clinical application of patient-specific pluripotent stem cells.
abstract: Induced pluripotent stem (iPS) cells are generated by epigenetic reprogramming of somatic cells through the exogenous expression of transcription factors. These cells, just like embryonic stem cells, are likely to have a major impact on regenerative medicine, because they self-renew and retain the potential to be differentiated into all cell types of the human body. In this Review, we describe the current state of iPS cell technology, including approaches by which they are generated and what is known about their biology, and discuss the potential applications of these cells for disease modeling, drug discovery, and, eventually, cell replacement therapy.
authors.affiliation: The Stowers Medical Institute, Harvard Stem Cell Institute, Department of Stem Cell and Regenerative Biology, Harvard University, 7 Divinity Avenue, Cambridge, MA 02138, USA. ekiskinis@mcb.harvard.edu
authors.forename: Evangelos
authors.initials: E
authors.lastname: Kiskinis
authors.forename: Kevin
authors.initials: K
authors.lastname: Eggan
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000628:therapy; D000818:Animals; D002454:Cell Differentiation; D055808:Drug Discovery; D053595:Embryonic Stem Cells / Q000502:physiology / Q000637:transplantation; D006801:Humans; D051379:Mice; D010300:Parkinson Disease / Q000628:therapy; D039904:Pluripotent Stem Cells / Q000502:physiology / Q000637:transplantation*